Role of Fractalkine-CX3CR1 Axis in Acute Rejection of Mouse Heart Allografts Subjected to Ischemia Reperfusion Injury

Taichi Kanzawa¹, Daisuke Tokita¹,²*, Kan Saiga¹,³*, Takafumi Yamakawa¹, Hidetoshi Ishigooka¹, Hironori Fukuda¹, Haruki Katsumata¹, Satoshi Miyairi¹, Rumi Ishii¹, Toshihito Hirai¹, Toshio Imai⁴, Masayoshi Okumi¹ and Kazunari Tanabe¹

¹Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan, ²Clinical and Academic Research Promotion Center, Tokyo Women's Medical University, Tokyo, Japan, ³Department of Urology, Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan, ⁴KAN Research Institute Inc., Kobe, Japan

Transplantation outcomes are affected by the increase in rejection associated with ischemia reperfusion injury (IRI). Fractalkine (FKN), a chemokine for recruitment of CX3CR1+ leukocytes, contributes to the pathogenesis of various inflammatory diseases. Herein, we evaluated the importance of the FKN-CX3CR1 axis during IRI-related rejections using a mouse heterotopic heart transplantation model. FKN expression and graft survival was compared between wild-type C57BL/6 recipients transplanted with BALB/c hearts preserved for 8 (WT-IRI) and 0.5 h (WT-control) at 4°C. Graft survival of WT-IRI was shorter than that of WT-control. FKN was expressed on the vascular endothelium in WT-IRI allografts, but minimally in WT-control. The role of the FKN-CX3CR1 axis in IRI-related rejection was directly investigated using the transplant model with CX3CR1-deficient recipients (CX3CR1 KO-IRI) or treatment with anti-mouse FKN monoclonal antibodies. Graft survival of CX3CR1 KO-IRI was longer than that of WT-IRI; antibody treatment prolonged graft survival. The contribution of CX3CR1+ monocytes to IRI-related rejection was evaluated by adoptive transfer to CX3CR1 KO-IRI. Adoptive transfer of CX3CR1+ monocytes attenuated the effect of prolonged graft survival in CX3CR1 KO-IRI. Overall, the FKN-CX3CR1 axis plays a major role during IRI-related rejection; its blockade has the potential to improve the outcomes of deceased donor transplantation.

Keywords: transplantation, rejection, ischemia-reperfusion injury, fractalkine, CX3CR1, monocyte

INTRODUCTION

Generally, organs transplanted from living donors have superior function and survival compared with those from deceased donors. The longer the ischemic time imposed on grafts, the lower their function and patient survival rates, which are related to promotion of graft rejection in ischemia reperfusion injury (IRI) (1–8). Length of ischemic time is connected to the severity of primary graft

Abbreviations: CTLA4-Ig, cytotoxic T lymphocyte antigen 4-immunoglobulin; FITC, fluorescein isothiocyanate; FKN, fractalkine; IL, interleukin; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; ICAM-1, intercellular adhesion molecule-1; IFN, interferon; IRI, ischemia reperfusion injury; mAb, monoclonal antibody; MST, median survival time; PE, phycoerythrin; TACE, TNFα cleavage enzyme; TNF, tumor necrosis factor; VCAM-1, vascular cell adhesion molecule-1.
dysfunction caused by the generation of oxygen radicals and activation of complement and endothelial cell dysfunction soon after the restoration of blood flow (9–11). During the early inflammatory process after reperfusion, the production of proinflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6, is greatly increased, and these cytokines induce and enhance alloimmune responses with the expression of adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), on vascular endothelium, leukocyte infiltration, and tissue injury in grafts (11–14). Increased graft-infiltrating neutrophils, monocytes, and memory CD8⁺ T cells have been observed in donor organs subjected to prolonged cold ischemia, and these immune cells are implicated in graft dysfunction and transplant rejection (2, 15). Therefore, control of inflammatory cell infiltration in the initial process could be an effective approach to improve graft survival in allogeneic transplantation with donor organs subjected to prolonged ischemic conditions.

Fractalkine (FKN) is the only CX3C chemokine reported to date (16, 17). FKN expression is induced by stimulation of proinflammatory cytokines, such as TNF-α, IL-1, and interferon (IFN)-γ, and the translation product is expressed as a membrane-bound form on vascular endothelial cells (16). Membrane-bound FKN is cleaved by metalloproteinases, including TNF-α cleavage enzyme (TACE) and ADAM10, and released into the blood (18, 19). Soluble FKN acts as a chemokine that migrates immune cells expressing the FKN receptor, CX3CR1 (20), through integrin-independent and -dependent mechanisms (21). CX3CR1-expressing cells include a variety of leukocytes, such as monocytes, macrophages, cytotoxic effector lymphocytes, and natural killer (NK) cells, which migrate along a gradient of soluble FKN and enter through membrane-bound FKN expressed on the endothelium at inflamed sites (16, 22). The FKN-CX3CR1 axis is thought to be involved in the initiation of the innate immune system as well as the continuation of acquired immune response, and is known to play a role in immune defense against infections and tumors (23–27).

In contrast, FKN reportedly contributes to the pathological process of vascular and tissue injury in inflammation-mediated diseases and pathological conditions, including atherosclerosis, glomerulonephritis, rheumatoid arthritis, and transplant rejection, by enhancing migration and adhesion of CX3CR1-expressing leukocytes and promoting their transmigration to inflammatory sites (24, 27, 28). In a mouse heart transplantation model, FKN expression was increased in rejecting grafts, and anti-CX3CR1 neutralizing antibody treatment substantially prolonged graft survival (29). Prophylactic or therapeutic administration of anti-FKN monoclonal antibodies to a mouse collagen-induced arthritis model suppressed the migration of osteoclast progenitor cells derived from a monocyte/macrophage lineage of bone marrow cells into the joint while markedly improving synovitis and joint destruction (30). Furthermore, antibody clone 5H8 reduced skin fibrosis in a systemic sclerosis model (31).

Fractalkine has been reported to exert an effect on monocytes. CD14⁺ monocytes express CX3CR1 (20), and FKN induces migration (16) and enhances integrin-dependent cell adhesion in monocytes (21,32,33). It has also been documented that CX3CR1 regulates the retention of inflammatory monocytes in blood vessels during inflammation (34). In addition, migration of inflammatory monocytes via a mechanism dependent on the FKN-CX3CR1 axis has been reported to play an important role in renal injury after ischemia reperfusion by cross-clamping kidney pedicles (35). The FKN-CX3CR1 axis is also associated with the
patrolling behavior of CD115$^+$Gr-1$^{low/-}$ monocytes crawling over the venous endothelium of the inflamed colon in a colitis model, locally producing proinflammatory cytokines and chemokines that promote subsequent leukocyte activation and infiltration. Anti-FKN antibody rapidly eliminated these crawling monocytes and inhibited their patrolling behavior (36).

To date, there have been many reports concerning the FKN-CX3CR1 axis and monocytes in inflammation-mediated pathogenesis, but their relevance to IRI-induced enhancement of rejection that occurs from an early stage after transplantation (IRI-related rejection) has not yet been fully clarified. We here assumed that FKN expression would be induced in grafts under long-term ischemia conditions and that monocytes infiltrated via the FKN-CX3CR1 axis have a significant impact on promotion of transplant rejection and graft failure. In the present study, we investigated the role of the FKN/CX3CR1 axis in a mouse model of IRI-related rejection using CX3CR1-deficient mice as recipients or an intervention with anti-mouse FKN neutralizing antibody (anti-FKN mAb), the emphasis being on the contribution of CX3CR1-positive monocytes.

**MATERIALS AND METHODS**

**Animals**

Male BALB/c and C57BL/6 mice were purchased from the Japan SLC Corporation (Hamamatsu, Japan). CX3CR1 homogenous knockout in C57BL/6 background mice was performed by KAN Research Institute (Kobe, Japan). All mice were bred and maintained under specific pathogen-free conditions at the Institute of Laboratory at Tokyo Women’s Medical University (Tokyo, Japan). The pathogen-free conditions implemented were based on the criteria of the Central Institute for Experimental Animals (Kawasaki, Japan). The Tokyo Women’s Medical University internal committee on the use and care of laboratory animals approved all experiments (Reference ID: AE19-081).

**Ectopic Heart Transplantation**

All transplant procedures were performed under general anesthesia using sevoflurane. Fully vascularized ectopic heart grafts from BALB/c donors were transplanted into C57BL/6 or CX3CR1-deficient recipients using microsurgical techniques (37). To investigate the influence of IRI on allograft rejection, ectopic heart transplantation was performed after donor hearts were preserved at 4°C for 8 h (prolonged cold ischemia: IRI) or 0.5 h (minimal cold ischemia: non-IRI control) (15). Cytotoxic T lymphocyte antigen 4-immunoglobulin (CTLA4-Ig) (ORENCA™, Bristol-Myers Squibb, Lawrenceville, NJ, United States) was administered intraperitoneally at a dose of 0.25 mg/day on the day of transplantation (day 0) and day 1. Graft engraftment was assessed by palpation with the presence of contraction as an indicator. Rejection was defined as complete cessation of contraction.

**Immunofluorescence Analysis**

After perfusion fixation with 1% paraformaldehyde, heart grafts were collected and embedded with O.C.T. compound (Sakura Finetek Japan Co., Ltd, Tokyo, Japan). The tissues were cut into 6 μm-thick sections, blocked with normal donkey serum, and stained with 10 μg/ml of goat anti-rat FKN antibody (R&D Systems, Inc., Minneapolis, MN, United States) and 50-fold diluted rabbit anti-mouse CD31 antibody (Abcam Plc, Cambridge, UK). The combination of 500-fold diluted Alexa fluor 555-conjugated donkey anti-goat IgG (Abcam) and Alexa fluor 488-conjugated goat anti-rabbit IgG (Abcam) was employed as the set of secondary antibodies. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI).

**Pathological Analysis**

Grafts were procured at day 7 and hematoxylin-eosin staining was performed after fixation with 10% neutral phosphate-buffered formalin.

**Administration of anti-FKN mAb**

Anti-FKN mAb (clone 5H8) and control IgG (anti-dinitrophenol mAb) (30, 31, 36) were provided by KAN Research Institute. Anti-FKN mAb or control IgG was administered at 500 μg/head on days 1, 3, 7, 10, and 14.

**Isolation and Adoptive Transfusion of CX3CR1-Positive Monocytes**

Bone marrows recovered from 10 week-old wild-type C57BL/6 mice were treated with ammonium chloride buffer for hemolysis, and cultured for 3 days at 37°C in RPMI 1640 medium supplemented with 50 ng/ml of recombinant mouse macrophage colony-stimulating factor (R and D Systems), 10% fetal bovine serum, 0.1 mM 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid (HEPES) (pH 7.2–7.5), 1× MEM non-essential amino acid solution, 1 mM sodium pyruvate, 1× penicillin-streptomycin, and 100 μM 2-mercaptoethanol. Monocytes were isolated from post-culture cells using the CD115 MicroBead Kit (mouse; Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany). The isolated monocytes were transferred into CX3CR1-deficient recipients at 3×10⁶/head on day−1.

To confirm the purity of CX3CR1-positive monocytes in the isolated cells, Fc blocking with anti-CD16/CD32 antibody (BD Bioscience, San Jose, CA, United States) was followed by staining with phycoerythrin (PE)-conjugated mouse CX3CR1 antibody and fluorescein isothiocyanate (FITC)-conjugated CD11b (AFS98; Tonbo Biosciences, San Diego, CA, United States) and FlowJo software (Tree Star, Ashland, OR, United States).

**Statistical Analysis**

Comparisons of graft survival were analyzed by the log-rank test using Prism seven software (GraphPad Software, La Jolla, CA, United States); differences with p values <.05 were considered significant.
RESULTS
Enhanced Acute Rejection and Increased Expression of FKN on Vascular Endothelial Cells in Allografts Subjected to Longer Cold Ischemia.

To investigate the influence of IRI on allograft rejection, ectopic heart transplantation was performed on wild-type C57BL/6 recipients after donor hearts were preserved at 4°C for 8 h (WT-IRI; n = 6) or 0.5 h (WT-control; n = 10). CTLA4-Ig was administered intraperitoneally at a dose of 0.25 mg/day on the day of transplantation (day 0) and on day 1. (A) Graft survival. The comparison between groups was analyzed via the log-rank test. (B) Hematoxylin-eosin-stained images of graft tissues at day 3 and 7. (C) Expression of fractalkine (FKN) in graft tissues at day 3. Immunofluorescence staining was performed using anti-FKN (red) and anti-CD31 antibodies (green). Nuclei were stained with DAPI (blue).

Histopathological findings at day 3 and 7 showed more severe cell infiltration in the WT-IRI group than in the WT-control group (Figure 1B). These results suggest that IRI was associated with enhanced graft rejection from the initial process (IRI-related rejection) and shortened graft survival in the WT-IRI group. To compare the expression of FKN in graft tissues between both groups, an immunofluorescence assay using anti-FKN antibody was performed on heart allografts at day 3. As shown in Figure 1C, FKN was strongly expressed on vascular endothelial cells in the WT-IRI group, which showed enhanced rejection and shortened graft survival compared to the WT control group, whereas less FKN signal was detected in the WT control group. In conclusion, the induction of FKN expression in vascular endothelial cells in graft tissues was
FIGURE 2 | Loss of influence of ischemia-reperfusion injury on graft survival in CX3CR1-deficient recipients. CX3CR1-deficient mice (C57BL/6 background) were transplanted with BALB/c donor hearts preserved at 4°C for 8 h (CX3CR1 KO-IRI: n = 8) or 0.5 h (CX3CR1 KO-control: n = 8). CTLA4-Ig was administered intraperitoneally at a dose of 0.25 mg/day on the day of transplantation (day 0) and day 1. (A) Graft survival. The CX3CR1 KO-IRI group was compared with the CX3CR1 KO-control group or the WT-IRI group (see Figure 1). The comparisons were analyzed via the log-rank test. (B) Hematoxylin-eosin-stained images of graft tissues at day 7.

FIGURE 3 | Preventive effect of anti-fractalkine monoclonal antibody (anti-FKN mAb) treatment on reduced allograft survival caused by cold ischemia. We transplanted BALB/c hearts preserved for 8 h at 4°C into wild-type C57BL/6 mice and treated with anti-FKN mAb (WT-IRI + anti-FKN mAb: n = 8) or control IgG (WT-IRI + control IgG: n = 8). Anti-FKN mAb clone 5 H8 was administered at 500 μg on the day before transplantation (day−1) and on days 3, 7, 10, and 14. CTLA4-Ig was administered intraperitoneally at a dose of 0.25 mg/day on days 0 and 1. (A) Graft survival. The comparison between groups was analyzed via the log-rank test. (B) A hematoxylin-eosin-stained image of graft tissues at day 3 and 7 in the WT-IRI + anti-FKN mAb group.
dependent on IRI, which might affect IRI-related rejection and shortening graft survival.

**Lack of Influence of IRI on Allograft Survival in CX3CR1-Deficient Recipients**

To investigate the relevance of the FKN receptor, CX3CR1, with respect to augmentation of acute rejection associated with cold ischemia, we transplanted BALB/c donor hearts preserved at 4°C for 8 h (CX3CR1 KO-IRI) or 0.5 h (CX3CR1 KO-control) into CX3CR1-deficient recipients. As shown in Figure 2A, there is no significant difference in graft survival between the CX3CR1 KO-IRI group (MST: 57.5 days) and the CX3CR1 KO-control group (MST: 66.5 days). Inflammatory cell infiltration in grafts at day 7 in both groups was similarly mild (Figure 2B). Furthermore, graft survival of the CX3CR1 KO-IRI group was significantly longer than that of the WT-IRI group ($p = .0226$, log-rank test) (Figure 2A). These results suggest that the presence of CX3CR1 molecules in recipients would be essential for IRI-related rejection.

**Improved Survival of Allografts Subjected to IRI in Wild-Type Recipients Receiving Anti-FKN mAb**

To further investigate the association between the FKN-CX3CR1 axis and IRI-related augmentation of rejection, we compared the survival of heart grafts subjected to cold ischemia in wild-type recipients with anti-FKN mAb treatment (WT-IRI + anti-FKN mAb) to those with control IgG treatment (WT-IRI + control IgG). As shown in Figure 3A, the WT-IRI + anti-FKN mAb group had a longer survival than the WT-IRI + control IgG group (MST: WT-IRI + anti-FKN mAb = 40.5 days vs WT-IRI + control IgG = 29.5 days; $p = .0204$, log-rank test). This result indicates that anti-FKN mAb treatment improves graft survival shortened by cold-ischemia conditions, confirming the importance of the FKN-CX3CR1 axis in IRI-related rejection. We compared the graft tissues at day 3 and 7 between the WT-IRI + anti-FKN mAb group (Figure 3B) and the WT-IRI group (Figure 1B) and found that the administration of anti-FKN mAb resulted in milder cellular infiltration (Figure 3B). These results indicate that blockade of the FKN-CX3CR1 axis inhibits IRI-related rejection.

**Importance of CX3CR1-Positive Monocytes in IRI-Related Rejection**

We focused on CX3CR1-positive monocytes as effector cells essential for enhancing acute rejection of grafts subjected to prolonged cold ischemia. C57BL/6 bone marrow cells were cultured under M-CSF stimulation for 3 days, and monocytes were purified with anti-CD115 antibody. Flow cytometry analysis showed that more than 93% of the isolated cells were CX3CR1-positive monocytes (Figure 4A). Approximately 3 × 10⁶ of the isolated cells were transferred into CX3CR1-deficient mice. The next day, donor hearts preserved for 8 h at 4°C were transplanted into the mice (CX3CR1 KO-IRI + CX3CR1+ Mono). As shown in Figure 4B, graft survival in the CX3CR1 KO-IRI group was significantly prolonged as compared to that in the WT-IRI group; adoptive transfer of CX3CR1-positive monocytes attenuated the effect of prolongation of graft survival. As a result of CX3CR1-positive monocyte infusion, there was no significant difference in graft survival between the CX3CR1 KO-IRI + CX3CR1+ Mono group (MST: 37.0 days) and the WT-IRI group (MST: 26.0 days). These results indicate that CX3CR1-positive monocytes are important effector cells in IRI-related rejection.

**DISCUSSION**

Prevention and mitigation of the impact of IRI is critical for protection against graft dysfunction and improvement of graft survival if the grafts have been ischemic for a long-time following
recovery from donors. For this purpose, regulation of immune cell infiltration in grafts during the initial process would be highly effective. The FKN-CX3CR1 axis plays an important role in immune defense by controlling the migration and adhesion of various types of immune cells involved in immune responses at inflammatory sites or infected areas. Furthermore, the FKN-CX3CR1 axis has been reported to be involved in the development of inflammation-associated diseases and pathological conditions. Using a murine ectopic transplantation model with hearts subjected to cold ischemia, the present study clarified the importance of the FKN-CX3CR1 axis and CX3CR1-positive monocytes in IRI-related rejection, and then demonstrated the potential of the FKN-CX3CR1 axis as a target for prevention of post-transplant graft dysfunction and rejection of long-term preserved grafts, such as those recovered from deceased donors.

In the present study, we first analyzed the influences of cold ischemic time on grafts in a mouse heart transplantation model. The comparison between the grafts preserved for 8 h at 4 °C (IRI) and 0.5 h (non IRI; control) showed that graft survival in the WT-IRI group was significantly shorter than that in the WT-control group (Figure 1A), and more severe cell infiltration was observed in the graft pathology of the WT-IRI group as early as day 3 (Figure 1B). FKN expression on vascular endothelial cells was detected at day 3 in the WT-IRI group, but minimally in the WT-control group (Figure 1C). These results suggest that FKN expression on graft vascular endothelial cells increases infiltrating cells from an early stage and correlates with the severity of IRI-related rejection. It has been previously reported that the expression of FKN on endothelial cells was induced by proinflammatory cytokines, such as IL-1, IFN-γ, and TNF-α (16). Cold ischemia induced activation of the transcription factor, NF-κB, and consequently elevated expression of TNF-α in rat liver allografts (38). The increased levels of IL-1β, IL-6, and TNF-α in human renal graft vein plasma were observed during reperfusion after cold ischemia (39). From the previous findings and our own data here, we infer that in the WT-IRI group, the expression of FKN on endothelial cells would be facilitated by proinflammatory cytokines greatly induced in grafts subjected to IRI. Proinflammatory cytokines also regulate expression of various cell adhesion molecules (40, 41). Cold ischemia leads to expression of P-selectin and ICAM-1 on the endothelium, and augments allogeneic-mediated cell infiltration in rat kidney allografts (42). ICAM-1 antisense oligodeoxynucleotides prevent reperfusion injury and enhance immediate graft function during renal transplantation (13). The engagement of the FKN-CX3CR1 and integrin-ICAM-1 axes enhanced cell adhesion compared to each axis alone (24, 32, 43). Within the allografts subjected to cold ischemia in the WT-IRI group, cooperation of FKN with other molecules associated with cell adhesion would result in increasing infiltrating cells that correlates with the severity of IRI-related rejection.

Graft rejection in the present model is further complicated by influences of allogeneic immunity and IRI caused by cold ischemia. In this study, all experimental groups received intraperitoneal administration of CTLA4-Ig at a dose of 0.25 mg on the day of heart transplantation and the next day. CTLA4-Ig suppresses priming of alloimmune responses by inhibiting T-cell activation mediated by the CD28/CD80/CD86 co-stimulatory signals in antigen presentation (44–46) but reportedly has little in the way of suppressive effects on transplant rejection of allografts subjected to cold ischemia (15). In our preliminary study of recipients not receiving CTLA4-Ig, both grafts preserved for 8 h at 4 °C and 0.5 h were rejected within 7 days and there was no difference in graft survival between them (data not shown). Acute rejection in these groups is thought to be predominantly caused by alloimmune responses owing to T-cell activation, which was independent of the influences of cold ischemia. The difference in graft survival between the WT-IRI and WT-control groups detected in the present study would be mainly based on IRI as they all survived over 7 days, the maximum survival when not receiving CTLA4-Ig that mitigates the effect of allogeneic immunity.

Next, to examine the importance of the FKN-CX3CR1 axis for graft rejection in cold-ischemic heart transplantation, we analyzed changes in graft survival employing CX3CR1-deficient mice as recipients or treatment with anti-FKN monoclonal antibodies. As shown in Figure 2A, in cases of transplantation with hearts subjected to cold ischemia for 8 h, CX3CR1-deficient recipients (CX3CR1 KO-IRI) exhibited prolonged graft survival compared to wild-type recipients (WT-IRI). As previously demonstrated, there is a significant difference in graft survival between donor hearts subjected to cold ischemia or not in wild-type recipients (Figure 1A: WT-IRI vs WT-control), but not in CX3CR1-deficient recipients (Figure 2A: CX3CR1 KO-IRI vs CX3CR1 KO-control). These results indicate that the loss of the FKN receptor, CX3CR1, almost completely abolishes the negative influence of cold ischemia on graft survival. Furthermore, when anti-FKN mAb was administered to the wild-type recipients transplanted with hearts subjected to prolonged cold ischemia (WT-IRI + anti-FKN mAb), a significant improvement in graft survival was observed (Figure 3). Taken together with these findings, the FKN-CX3CR1 axis plays a major role in IRI-related rejection.

Although we showed evidence herein for the relationships involving the FKN-CX3CR1 axis-mediated promotion of graft rejection owing to IRI, the importance of the FKN-CX3CR1 axis in allogeneic acute rejection has already been reported. During mouse heart transplantation, FKN expression was increased in the rejecting allografts and was prominent on vascular tissues and endothelium at early time points. Anti-FKN or anti-CX3CR1 antibodies inhibited the adhesion of peripheral blood mononuclear cells to the vascular endothelium, and treatment with anti-CX3CR1 antibody significantly prolonged survival of mouse cardiac allografts (29). Moreover, when CX3CR1 knockout mice were used as recipients, graft survival was prolonged in the presence of subtherapeutic levels of cyclosporin A with a concomitant reduction in infiltrating macrophages, NK cells, and other leukocytes observed in the grafts (28). These studies highlighted the importance of the FKN-CX3CR1 axis during the pathogenesis of
acute transplant rejection. Based on these findings along with the present data, the FKN-CX3CR1 axis appears to be an effective target for not only preventing acute rejection but also controlling IRI-dependent promotion of rejection responses, suggesting that neutralizing antibodies or other blockers targeting the axis could contribute to protect the long-term preserved donor organs from graft failure.

Next, to evaluate the potential of CX3CR1-positive monocytes as immune cells that exert effector function during IRI-related rejection, CX3CR1-deficient recipients adoptively transferred with monocytes isolated from wild-type mice were transplanted with donor hearts subjected to prolonged cold ischemia (CX3CR1 KO-IRI + CX3CR1 Mono). As shown in Figure 4B, no significant difference was found in graft survival between the CX3CR1 KO-IRI + CX3CR1 Mono and WT-IRI groups. Moreover, CX3CR1-deficient recipients without transferring monocytes (CX3CR1 KO-IRI) exhibited prolonged survival compared to the WT-IRI group (Figure 1A). These results demonstrate that CX3CR1-positive monocytes play an important role in IRI-related rejection in the present model, suggesting that inhibition of monocyte migration through the FKN-CX3CR1 axis may have contributed to the improvement in graft survival shown using CX3CR1-deficient mice as recipients or by treatment with anti-FKN mAb. It has been reported that acute allograft dysfunction is closely related to monocyte infiltration and the monocye/macrophage lineage cells function as effectors of allograft damage and activate allogeneic responses during acute allograft rejection (47–50). Monocytes that infiltrated into allografts through the FKN-CX3CR1 axis may have contributed to enhancement of graft rejection through similar mechanisms. Conversely, survival rates of the CX3CR1 KO-IRI + CX3CR1 Mono group were slightly higher than those of the WT-IRI group (Figure 4B), suggesting that a transfer of CX3CR1-positive monocytes alone may not fully restore the influence of IRI on grafts exerted in the WT-IRI group. In addition to monocytes, CX3CR1 is known to be expressed in effector memory CD8⁺ T cells (51). Reportedly, there was a direct association between increased durations of cold ischemic allograft preservation and numbers/enhanced functions of early graft-infiltrating endogenous memory CD8⁺ T cells, which directly mediate rejection of allografts subjected to prolonged ischemia (15). Although the present data have demonstrated the crucial role of CX3CR1-positive monocytes in graft damage correlated with reduced survival of cold-preserved allografts, analysis of the involvement of other CX3CR1-positive cells is an important topic for future research.

Thus, although there is still room for analysis of immune cells correlated with enhancement of rejection owing to cold ischemia, the importance of the FKN-CX3CR1 axis was clearly demonstrated in the present study. These results strongly suggest that the FKN-CX3CR1 axis may be useful as an interventional target for prophylaxis and therapy to improve survival of allografts affected by IRI. As an initial attempt at clinical application of FKN-CX3CR1 blockades, a humanized mAb against FKN, E6011, has been evaluated in a clinical trial for rheumatoid arthritis. No serious adverse events or deaths were reported in this study, indicating that the FKN-CX3CR1 blockade intervention is safe and well-tolerated, and may have a positive clinical effect in patients with highly active rheumatoid arthritis (52, 53). Based on the present study, clinical applications of FKN-CX3CR1 blockades even in the field of transplantation would be expected, and anti-FKN antibodies hold great promise as an interventional approach to protect grafts that have been left in an ischemic state for a long-time during preservation, such as organs from deceased donors, and to improve the outcomes of organ transplantation.

There are potential limitations to the present study. The following test have not been performed: 1) to compare the early-stage histopathology of the CX3CR1 KO-control, CX3CR1 KO-IRI and WT-IRI groups, 2) to compare the donor-reactive memory CD8⁺ T cells of wild-type and CX3CR1 KO mice, and 3) to confirm the infiltration of transplanted monocytes into graft tissues and early-stage histopathology. These rigorous analyses are necessary to further validate the role of the FKN-CX3CR1 axis in IRI-related rejection in the future.

In conclusion, ischemia in donor organs over time with respect to transplantation leads to exacerbation of graft rejection via impaired reperfusion after transplantation. CX3CR1-positive monocytes and the FKN-CX3CR1 axis play important roles in this series of tissue disorders that significantly affect allograft survival. Blockade of the FKN-CX3CR1 axis by anti-FKN antibodies or other means reduces the impact of IRI-related rejection and could be an effective intervention to improve the outcomes of deceased donor transplantation.
REFERENCES

1. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High Survival Rates of Kidney Transplants from Spousal and Living Unrelated Donors. N Engl J Med (1995) 333:333–6. doi:10.1056/nejm199508103330801

2. Jassem W, Koo DSH, Gerundolo L, Rela M, Heaton ND, Fuggle SV. Cadaveric versus Living-Donor Livers: Differences in Inflammatory Markers after Transplantation. Transplantation (2003) 76:1599–603. doi:10.1097/01.tp.0000010040.82135.dc

3. Hauptman PJ, Aranki S, Mudge GH, Jr, Couper GS, Loh E. Early Cardiac Allograft Failure after Orthotopic Heart Transplantation. Am Heart J (1994) 127:179–86. doi:10.1016/0002-8703(94)90523-1

4. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed Graft Function: Risk Factors and Implications for Renal Allograft Survival I. Transplantation (1997) 63:968–74. doi:10.1097/00001072-19970415-00011

5. Shoskes DA, Halloran PF. Delayed Graft Function in Renal Transplantation: Etiology, Management and Long-Term Significance. J Urol (1996) 155:1831–40. doi:10.1001/juro.1996.0106023-3

6. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the Donor Liver: Risk Factors for Poor Function after Orthotopic Liver Transplantation. Hepatology (1994) 20:829–38. doi:10.1001/hep.19840204010

7. Banner NR, Thomas HL, Curnow E, Hussey JC, Rogers CA, Bonser RS. The Importance of Cold and Warm Cardiac Ischemia for Survival after Heart Transplantation. Transplantation (2008) 86:542–7. doi:10.1097/tp.0b013e3181410f99

8. Salvadori M, Rosso G, Bertoni E. Update on Ischemia-Reperfusion Injury in Kidney Transplantation: Pathogenesis and Treatment. World J Transplant (2015) 5:52. doi:10.5500/wjt.v5.i2.52

9. Boros P, Bromberg JS. New Cellular and Molecular Immune Pathways in Ischemia/reperfusion Injury. Am J Transpl (2006) 6:652–8. doi:10.1111/j.1600-6143.2005.01228.x

10. Carden DL, Granger DN. Pathophysiology of Ischaemia-Reperfusion Injury. J Pathol (2000) 190:255–66. doi:10.1002/(sici)1096-9896(200002)190:3<255::aid-path526>3.0.co;2-6

11. Eltzschig HK, Ekle T. Ischemia and Reperfusion-From Mechanism to Translation. Nat Med (2011) 17:1391–401. doi:10.1038/nm.2507

12. Dragen D, Hoff U, Park JK, Qun Y, Schneider W, Lujt FC, et al. Ischemia-reperfusion injury in Renal Transplantation Is Independent of the Immunologic Background. Kidney Int (2000) 58:2166–77. doi:10.1111/j.1523-1755.2000.00390.x

13. Dragun D, Tullius SG, Park JK, Maasch C, Lukitch S, Lippoldt A, et al. ICAM-1 Antisense Oligodeoxynucleotides Prevent Reperfusion Injury and Enhance Immediate Graft Function in Renal Transplantation. Kidney Int (1998) 54:590–602. doi:10.1046/j.1523-1755.1998.00026.x

14. Ishii D, Schenk AD, Baba S, Fairchild RL. Role of TNFα in Early Chemokine Production and Leukocyte Infiltration into Heart Allografts. Am J Transpl (2010) 10:39–68. doi:10.1111/j.1600-6143.2009.02921.x

15. Su CA, Iida S, Abe T, Fairchild RL. Endogenous Memory CD8 T Cells Directly Mediate Cardiac Allograft Rejection. Am J Transpl (2014) 14:568–79. doi:10.1111/ajt.12655

16. Baran JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A New Class of Membrane-Bound Chemokine with a CX3C Motif. Nature (1997) 385:640–4. doi:10.1038/385640a0

17. Pan Y, Lloyd C, Zhou H, Dolkich S, Deeds J, Gonzalez J-A, et al. Neurotactin, a Neurotactin Membrane-Anchored Chemokine Upregulated in Brain Inflammation. Nature (1997) 387:611–7. doi:10.1038/42941

18. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, et al. Tumor Necrosis Factor-a-Converting Enzyme (ADAM17) Mediates the Cleavage and Shedding of Fractalkine (CX3CL1). J Biol Chem (2001) 276:37993–8001. doi:10.1074/jbc.m106342200

19. Tsou C-L, Haskell CA, Charo IF. Tumor Necrosis Factor-α in Early Chemokine Expression and Molecular Characterization of Fractalkine Receptor CX3CR1, Which Mediates Both Leukocyte Migration and Adhesion. Cell (1997) 91:521–30. doi:10.1016/s0022-5347(00)80438-9

20. Goda S, Imai T, Yoshide O, Yoneda O, Inoue H, Nagano Y, et al. CX3C-chemokine, Fractalkine-Enhanced Adhesion of THP-1 Cells to Endothelial Cells through Integrin-dependent and -independent Mechanisms. J Immunol (2000) 164:4313–20. doi:10.4049/jimmunol.164.8.4313

21. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima H, Kikazaki M, et al. Dual Functions of Fractalkine/CX3C Ligand 1 in Trafficking of Perforin+/Granzyme B+ Cytotoxic Effector Lymphocytes that Are Defined by CX3CR1 Expression. J Immunol (2002) 168:6173–80. doi:10.4049/jimmunol.168.12.6173

22. Gerard C, Rollins BJ, Chemokines and Disease. Nat Immunol (2001) 2:108–15. doi:10.1038/841209

23. Umehara H, Bloom E, Okazaki T, Domae N, Imai T. Fractalkine and Vascular Injury. Trends Immunol (2001) 22:602–7. doi:10.1016/s1471-4906(01)02051-8

24. Nelson PJ, Krenskey AM, Chemokines, Chemokine Receptors, and Allograft Rejection. Immunity (2001) 14:377–86. doi:10.1016/s1074-7613(01)00118-2

25. Umehara H, Imai T. Role of Fractalkine in Leukocyte Adhesion and Migration and in Vascular Injury. Drug News Perspect (2001) 14:460. doi:10.1358/dnp.2001.14.8.58415

26. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshide O, Imai T. Fractalkine in Vascular Biology. Arteriosclerosis, Thromb Vasc Biol (2004) 24:34–40. doi:10.1161/01.ATV.010.000953.602479.1f

27. Haskel CA, Hancock WW, Salant DJ, Gao W, Czazdima V, Peters W, et al. Targeted Deletion of CX3CR1 Reveals a Role for Fractalkine in Cardiac Allograft Rejection. J Clin Invest (2001) 108:679–88. doi:10.1172/jci12976

CONFLICT OF INTEREST

Author TI is employed by the company KAN Research Institute, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ACKNOWLEDGMENTS

During this research, we used instruments from the Medical Research Institute, Tokyo Women’s Medical University. The authors would like to thank H. Ishizaki and Y. Ono for the generation of CX3CR1–KO mice. In addition, we thank all members of KAN Research Institute for the helpful discussion and advice.
29. Robinson LA, Nataraj C, Thomas DW, Howell DN, Griffiths R, Bautch V, et al. A Role for Fractalkine and its Receptor (CX3CR1) in Cardiac Allograft Rejection. *J Immunol* (2006) 165:6607–72. doi:10.4049/jimmunol.165.11.6607

30. Hoshino-Negishi K, Okkuro M, Nakatani T, Kuboi Y, Nishimura M, Ida Y, et al. Role of Anti-fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis. *Arthritis Rheumatol* (2019) 71:222–31. doi:10.1002/art.40688

31. Luong VH, Tsunemiwa Y, Chino T, Doanh LH, Matsushita T, Obara T, et al. The Technique for Heterotopic Cardiac Transplantation in Mice: Fractalkine-CX3CR1 Axis in IRI-Related Rejection. *Transplantation* (2020) 109:2270–9. doi:10.1097/TP.0000000000001722

32. Umehara H, Goda S, Imai T, Nagano Y, Minami Y, Tanaka Y, et al. Fractalkine, a CX3 C-Chemokine, Functions Predominantly as an Adhesion Molecule in Monocytic Cell Line THP-1. *Immunol Cell Biol* (2001) 79:298–302. doi:10.1046/j.1440-1711.2001.01004.x

33. Chapman GA, Moores KE, Gohil J, Berkhout TA, Patel L, Green P, et al. Role of Fractalkine in the Recruitment of Monocytes to the Endothelium. *Eur J Pharmacol* (2000) 392:189–95. doi:10.1016/s0160-028x(00)0014-2999(00)01117-5

34. Hamon P, Loyher P-L, Baudesson de Charvill C, Licata F, Combadière C, Boissonnas A. CX3CR1-dependent Endothelial Margination Modulates Ly6Chigh Monocyte Systemic Deployment upon Inflammation in Mice. *Blood* (2017) 129:296–307. doi:10.1182/blood-2016-08-732164

35. Li L, Huang L, Suny S-SJ, Vergis AL, Rosin DL, Rose CE, et al. The Chemokine Receptors CCR2 and CX3CR1 Mediate Monocyte/macrophage Trafficking in Kidney Ischemia-Reperfusion Injury. *Kidney Int* (2008) 74:1526–37. doi:10.1038/ki.2008.500

36. Kubo Y, Nishimura M, Ikeda W, Nakatani T, Seki Y, Yamaura Y, et al. Blockade of the Fractalkine-Cx3cr1 axis Ameliorates Experimental Colitis by Dislodging Venous Crawling Monocytes. *Int Immunol* (2019) 31:287–302. doi:10.1093/intimm/dxz006

37. Niimi M. The Technique for Heterotopic Cardiac Transplantation in Mice: Experience of 3000 Operations by One Surgeon. *J Heart Lung Transplant* (2001) 20:1123–8. doi:10.1016/s1053-2498(01)00309-6

38. Gu X-P, Jiang Y, Xu F-T, Qiu Y-D, Ding Y-T. Effect of Cold-Ischemia Time on Kidney Ischemia-Reperfusion Injury. *World J Gastroenterol* (2004) 10:1000. doi:10.3748/wjg.v10.i7.1000

39. Domanski L, Pawlik A, Safrazow K, Jakubowska K, Dziedziejko V, Chlubek D, et al. Purine and Cytokine Concentrations in the Renal Vein of the Allograft at the End of Ischemia. *Transplant Proc* (2007) 39:1319–22. doi:10.1016/j.transproceed.2006.11.022

40. Thornhill MH, Hasard DO. IL-4 Regulates Endothelial Cell Activation by IL-1, Tumor Necrosis Factor, or IFN-Gamma. *J Immunol* (1990) 145: 865–72.

41. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzæg P. Cytokine-regulated Expression of E-Selectin, Intercellular Adhesion Molecule-1 (ICAM-1), and Vascular Cell Adhesion Molecule-1 (VCAM-1) in Human Microvascular Endothelial Cells. *J Immunol* (1996) 156:2558–65.

42. Kouwenhoven EA, de Bruijn RWF, Bajema IM, Marquet RL, Ijzermans JNM. Cold Ischemia Augments Allogeneic-Mediated Injury in Rat Kidney Allografts. *Kidney Int* (2001) 59:1142–8. doi:10.1046/j.1525-1755.2001.01000.x

43. Kerfoot SM, Lord SE, Bell RB, Gill V, Robbins SM, Kubes P. Human Fractalkine Mediates Leukocyte Adhesion but Not Capture under Physiological Shear Conditions; a Mechanism for Selective Monocyte Recruitment. *Eur J Immunol* (2003) 33:729–39. doi:10.1002/eji.200323502

44. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, et al. Long-term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA4Ig Plus Donor-specific Transfusion. *J Exp Med* (1993) 178:1801–6. doi:10.1084/jem.178.5.1801

45. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, et al. CD28-B7 Blockade after Alloantigenic challenge In Vivo Inhibits Th1 Cytokines but Spares Th2. *J Exp Med* (1995) 181:1869–74. doi:10.1084/jem.181.5.1869

46. Bolling SF, Lin H, Wei R-Q, Linsley P, Turka LA. The Effect of Combination Cyclosporine and CTLA4-Ig Therapy on Cardiac Allograft Survival. *J Surg Res* (1994) 57:60–4. doi:10.1016/j.jss.2019.1110

47. Jose MD, Ikezumi Y, van Rooijen N, Atkins RC, Chadban SJ. Macrophages Act as Effectors of Tissue Damage in Acute Renal Allograft Rejection. *Transplantation* (2003) 76:1015–22. doi:10.1097/01.TP.0000083507.67995.13

48. QF J, Adair A, Ferenbach D, Vass DG, Mylonas KJ, Kipari T, et al. Depletion of Cells of Monocyte Lineage Prevents Loss of Renal Microvascularity in Murine Kidney Transplantation. *Transplantation* (2008) 86:1267–74. doi:10.1097/tp.0b01318188d433

49. Girlanda R, Kleiner DE, Duan Z, Ford EAS, Wright EC, Mannon RB, et al. Monocyte Infiltration and Kidney Allograft Dysfunction during Acute Rejection. *Am J Transpl* (2008) 8:600–7. doi:10.1111/j.1600-6143.2007.02109.x

50. Ma FY, Woodman N, Mulley WR, Kanelis J, Nikolic-Paterson D. Macrophages Contribute to Cellular but Not Humoral Mechanisms of Acute Rejection in Rat Renal Allografts. *Transplantation* (2013) 96:949–57. doi:10.1097/tp.0b013e3182a5b9f3

51. Böttcher JP, Beyer M, Meissner F, Abdala H, Zander J, Hochst R, et al. Functional Classification of Memory CD8+ T Cells by CX3CR1 Expression. *Nat Commun* (2015) 6:3806. doi:10.1038/ncomms9306

52. Tanaka Y, Takeuchi T, Umehara H, Nanki T, Yasuda N, Tago F, et al. Safety, Pharmacokinetics, and Efficacy of E6011, an Antifractalkine Monoclonal Antibody, in a First-In-Patient Phase 1/2 Study on Rheumatoid Arthritis. *Mod Rheumatol* (2018) 28:58–65. doi:10.1080/14397595.2017.1337056

53. Nanki T, Imai T, Kawai S. Fractalkine/CX3CL1 in Rheumatoid Arthritis. *Mod Rheumatol* (2017) 27:392–7. doi:10.1080/14397595.2016.1213481

Copyright © 2022 Kanzawa, Tokita, Saiga, Yamakawa, Ishigooka, Fukuda, Katsumata, Miyari, Ishii, Hirai, Imai, Okumi and Tanabe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.